Undertaking human trials to assess vaccine safety
Following GMP manufacture, the safety of experimental vaccines must be determined in human trials. AVRA will collaborate with various national capabilities including CREEID, Vax4COVID, MACH and the Waratah Vaccine Trials Alliance.
AVRA will also facilitate advanced microbiologic and immunologic testing to define the mechanisms of action of vaccines and correlates of protection during early-stage human trials. This will provide critical data to develop more efficacious versions of first-generation vaccines and inform the development of others. AVRA will collaborate with Doherty and MCRI-led teams developing human volunteer challenge models using target pathogens for vaccine efficacy assessment.